| scholarly article | Q13442814 |
| P50 | author | Kent J. Weinhold | Q109935303 |
| Dani Bolognesi | Q109936341 | ||
| P2093 | author name string | H Mitsuya | |
| M H St Clair | |||
| P A Furman | |||
| S Broder | |||
| S N Lehrman | |||
| J A Fyfe | |||
| G A Freeman | |||
| J L Rideout | |||
| P2860 | cites work | 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | Q24609215 |
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Effect of acyclovir on the deoxyribonucleoside triphosphate pool levels in Vero cells infected with herpes simplex virus type 1 | Q28264714 | ||
| Purification, characterization, and comparison of the DNA polymerases from two primate RNA tumor viruses | Q36592972 | ||
| DNA polymerases of eukaryotes | Q39385854 | ||
| Kinetics of the interaction of monophosphates of the antiviral nucleosides 2'-fluoro-1-beta-D-arabinofuranosylpyrimidine and (E)-5-(2-bromovinyl)-2'-deoxyuridine with thymidylate kinases from Vero cells and herpes simplex virus types 1 and 2. | Q39849338 | ||
| Metabolism of acyclovir in virus-infected and uninfected cells | Q39855907 | ||
| Physical and biological consequences of incorporation of antiviral agents into virus DNA. | Q40080557 | ||
| Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine | Q40189782 | ||
| Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate | Q40292914 | ||
| Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with Herpesvirus genetic information | Q45106688 | ||
| Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine | Q45797876 | ||
| Isolation of murine sarcoma virus-transformed mouse cells which are negative for leukemia virus from agar suspension cultures | Q45822274 | ||
| Human thymidine kinase. Purification and properties of the cytosolic enzyme of placenta. | Q50928520 | ||
| Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions | Q68948939 | ||
| Phosphorylation of acyclovir diphosphate by cellular enzymes | Q70559957 | ||
| A novel method for phosphorylation of nucleosides to 5′-nucleotides | Q72372104 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| virology | Q7215 | ||
| zidovudine | Q198504 | ||
| phosphorylation | Q242736 | ||
| P304 | page(s) | 8333-7 | |
| P577 | publication date | 1986-11-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase | |
| P478 | volume | 83 |
| Q28316326 | (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro |
| Q55067568 | 19F NMR study of the uptake of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil in erythrocytes: evidence of transport by facilitated and nonfacilitated pathways. |
| Q44623511 | 2',3'-dideoxynucleoside triphosphates (ddNTP) and di-2',3'-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and Np4N counterparts as substrates of firefly luciferase, dinucleoside tetraphosphatase and phosphod |
| Q28379497 | 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. |
| Q36918604 | 3'-Azido-3'-deoxythymidine inhibits the replication of avian leukosis virus |
| Q77968145 | 3'-Azido-3'-deoxythymidine reduces the rate of transferrin receptor endocytosis in K562 cells |
| Q35562985 | 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase |
| Q37191116 | 3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation |
| Q41293185 | 3'-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations |
| Q73270018 | 3'-Azidothymidine significantly alters glycosphingolipid synthesis in melanoma cells and decreases the shedding of gangliosides |
| Q28368392 | 4'-Acylated thymidine 5'-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase |
| Q28367605 | 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile |
| Q28321395 | 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus |
| Q37784514 | A 40-Year Journey in Search of Selective Antiviral Chemotherapy* |
| Q42141365 | A Single Zidovudine (AZT) Administration Delays Hepatic Cell Proliferation by Altering Oxidative State in the Regenerating Rat Liver. |
| Q36499104 | A brief overview of mechanisms of mitochondrial toxicity from NRTIs |
| Q43996453 | A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects |
| Q40678103 | A computational model of mitochondrial AZT metabolism |
| Q28370658 | A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase |
| Q36134948 | A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography |
| Q41503684 | A novel assay system for anti-human immunodeficiency virus type 1 (HIV-1) activity using a subclone of a monocytic cell line, U937. |
| Q77916920 | A novel chemotherapeutic regimen (interferon alfa, zidovudine, and etretinate) for adult T-cell lymphoma resulting in rapid tumor destruction |
| Q39717304 | A photolabile 2',3'-dideoxyuridylate analog bearing an aryl(trifluoromethyl)diazirine moiety: photoaffinity labeling of HIV-1 reverse transcriptase |
| Q40466103 | A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission. |
| Q35849253 | A screen in Escherichia coli for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase |
| Q39531429 | A time-of-drug addition approach to target identification of antiviral compounds |
| Q42209697 | AIDS dementia: synthesis and properties of a derivative of 3'-azido-3'-deoxythymidine (AZT) that may become 'locked' in the central nervous system |
| Q33929729 | AIDS virus reverse transcriptase defined by high level expression in Escherichia coli |
| Q44292281 | AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells |
| Q39811548 | AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins |
| Q28371775 | AZT-5'-(p-bromophenyl methoxyalaninyl phosphate) as a potent and non-toxic anti-human immunodeficiency virus agent |
| Q41151945 | AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation |
| Q35122047 | Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus |
| Q34464355 | Actinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression. |
| Q110257032 | Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors |
| Q28335917 | Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1 |
| Q35912640 | Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine |
| Q54257052 | Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro. |
| Q38568978 | Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors |
| Q36096407 | Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection |
| Q39559552 | Advances in human retroviruses |
| Q34089694 | Aging and HIV/AIDS: pathogenetic role of therapeutic side effects |
| Q33527409 | Allosteric regulation of HIV-1 reverse transcriptase by ATP for nucleotide selection |
| Q35272996 | Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. |
| Q35212611 | Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics |
| Q48311794 | Amide-functionalized pillar[5]arenes as a novel class of macrocyclic receptors for the sensing of H2PO4- anion. |
| Q28379270 | An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine |
| Q68884044 | Analysis of 3'-azido-3'-deoxythymidine levels in tissues and milk by isocratic high-performance liquid chromatography |
| Q43766225 | Analysis of intracellular didanosine triphosphate at sub-ppb level using LC-MS/MS. |
| Q28316430 | Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion |
| Q28359820 | Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus |
| Q28328852 | Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives |
| Q28333679 | Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog |
| Q33977295 | Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. |
| Q42543077 | Anti-retroviral strategies for AIDS and related diseases |
| Q28361768 | Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U) |
| Q39900240 | Anticancer Conjugates and Cocktails Based on Methotrexate and Nucleoside Synergism |
| Q35322871 | Antiretroviral therapy: reverse transcriptase inhibition |
| Q67685039 | Antiviral Drug Resistance |
| Q40809188 | Antiviral activity of fattiviracin FV-8 against human immunodeficiency virus type 1 (HIV-1). |
| Q67514516 | Antiviral agents |
| Q40874319 | Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. |
| Q33586790 | Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q39152916 | Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date |
| Q38709585 | Antiviral therapy in human immunodeficiency virus infection |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q35118261 | Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q44533956 | Arabinosylcytosine downregulates thymidine kinase and induces cross-resistance to zidovudine in T-lymphoid cells |
| Q43258274 | Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. |
| Q34737674 | Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy |
| Q28340455 | Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma |
| Q33874792 | Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system |
| Q34368600 | Azidothymidine: crystal structure and possible functional role of the azido group |
| Q41856023 | Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate |
| Q35563298 | Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design |
| Q38890254 | Bis(benzoyloxybenzyl)-DiPPro nucleoside diphosphates of anti-HIV active nucleoside analogues |
| Q45423500 | Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors |
| Q34614908 | Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides |
| Q35682397 | Cellular issues relating to the resistance of HIV to antiretroviral agents. |
| Q41623558 | Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine |
| Q40283999 | Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus |
| Q44467962 | Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. |
| Q40885618 | Cellular phosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key intermediate in the activation of the antiviral agent DDI, in human peripheral blood mononuclear cells |
| Q71070039 | Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase |
| Q41447739 | Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase |
| Q44603165 | Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study |
| Q41505879 | Chemotherapeutic Options in HIV Infection |
| Q41729315 | Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions |
| Q35126325 | Clarithromycin does not affect phosphorylation of zidovudine in vitro |
| Q31030044 | Clinical pharmacokinetics of zidovudine. An overview of current data |
| Q40487397 | Clinical pharmacology of zidovudine and other 2?,3?-dideoxynucleoside analogues |
| Q37859395 | Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations |
| Q36588154 | Cloning, expression, purification, crystallization and preliminary X-ray crystallographic study of thymidylate kinase (TTHA1607) from Thermus thermophilus HB8 |
| Q34429315 | Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice |
| Q28342758 | Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro |
| Q28333667 | Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs |
| Q39785307 | Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes. |
| Q40886850 | Comparative pharmacokinetics of antiviral nucleoside analogues |
| Q54039226 | Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. |
| Q28323353 | Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus |
| Q28339707 | Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases |
| Q33761409 | Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells |
| Q35759090 | Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. |
| Q28318354 | Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine |
| Q44477319 | Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration |
| Q77360287 | Concentration-controlled zidovudine therapy |
| Q37937195 | Concepts and trends in antiviral chemotherapy in the period of AIDS: a review |
| Q34163065 | Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding |
| Q37346125 | Considerations for the antiretroviral management of women in 2008. |
| Q37391720 | Continuous microspectrophotometric measurement of DNA polymerase activity: application to the Klenow fragment of Escherichia coli DNA polymerase I and human immunodeficiency virus type 1 reverse transcriptase |
| Q44321257 | Correlation of micronuclei-induction with the cell survival in HeLa cells treated with a base analogue, azidothymidine (AZT) before exposure to different doses of gamma-radiation |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q54074101 | Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine. |
| Q38366289 | Curious discoveries in antiviral drug development: the role of serendipity |
| Q36951689 | Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro |
| Q72532937 | Cytotoxic and biochemical implications of combining AZT and AG-331 |
| Q36634833 | DNA Polymerases versus HIV Reverse Transcriptase in AIDS Therapy |
| Q77322585 | Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals |
| Q33820365 | Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. |
| Q54328043 | Denaturation/Refolding of Purified Recombinant HIV Reverse Transcriptase Yields Monomeric Enzyme with High Enzymatic Activity |
| Q38651297 | Design of some nucleic acid antimetabolites: expectations and reality |
| Q38503274 | Design, enantiopure synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives as a bioisostere of lamivudine |
| Q35174673 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides |
| Q38508397 | Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives |
| Q34540458 | Design, synthesis, and in vitro and in vivo biological studies of a 3'-deoxythymidine conjugate that potentially kills cancer cells selectively |
| Q45739489 | Determination at ppb level of an anti-human immunodeficiency virus nucleoside drug by capillary electrophoresis-electrospray ionization tandem mass spectrometry. |
| Q33978294 | Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry |
| Q33933498 | Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics |
| Q37789224 | Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41 |
| Q36196194 | Development of a Novel Plasmid-Free Thymidine Producer by Reprogramming Nucleotide Metabolic Pathways. |
| Q40408546 | Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus |
| Q33699597 | Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients |
| Q59944857 | Development of a novel 32P-postlabeling method for the analysis of 3′-azido-3′-deoxythymidine |
| Q36993425 | Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model |
| Q54034689 | Development of novel nucleoside analogues for use against drug resistant strains of HIV-1. |
| Q35530740 | Didanosine, a new antiretroviral drug. A review |
| Q28361679 | Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1 |
| Q39828007 | Different patterns of inhibition of avian myeloblastosis virus reverse transcriptase activity by 3'-azido-3'-deoxythymidine 5'-triphosphate and its threo isomer |
| Q45768310 | Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro |
| Q33754889 | Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells |
| Q33978880 | Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells |
| Q41869861 | Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation |
| Q39051706 | Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine |
| Q33900606 | Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells |
| Q34349394 | Differential susceptibility of retroviruses to nucleoside analogues |
| Q90696648 | Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples |
| Q43708853 | Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry. |
| Q36672092 | Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals |
| Q47948290 | Drug repurposing for the treatment of glioblastoma multiforme. |
| Q59352941 | Dynamic Interplay of RNA and Protein in the Human Immunodeficiency Virus-1 Reverse Transcription Initiation Complex |
| Q35816131 | Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages |
| Q36625650 | Effect of AZT on thymidine phosphorylation in cultured H9c2, U-937, and Raji cell lines. |
| Q36018600 | Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine |
| Q28347042 | Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro |
| Q33350615 | Effective modulation of the haematopoietic toxicity associated with zidovudine exposure to murine and human haematopoietic progenitor stem cells in vitro with lithium chloride |
| Q28316436 | Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma |
| Q35854248 | Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA |
| Q38908302 | Effects of azidothymidine on protein kinase C activity and expression in erythroleukemic cell K562 and acute lymphoblastic leukemia cell HSB-2. |
| Q41440096 | Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. |
| Q28325736 | Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture |
| Q39651748 | Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase |
| Q37335626 | Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine |
| Q36752735 | Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells |
| Q40909668 | Effects of zidovudine (AZT) and dideoxyinosine (ddI) on human trophoblast cells |
| Q38829114 | Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles |
| Q42451949 | Efficient retroviral gene transfer of a Tat-regulated herpes simplex virus thymidine kinase gene for HIV gene therapy. |
| Q42208409 | Efficient syntheses of [¹¹C]zidovudine and its analogs by convenient one-pot palladium(0)-copper(I) co-mediated rapid C-[¹¹C]methylation. |
| Q35174378 | Emergence of Mutant HIV Reverse Transcriptase Conferring Resistance to AZT |
| Q35859899 | Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells |
| Q40156157 | Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. |
| Q38336814 | Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer |
| Q39730794 | Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients |
| Q33747461 | Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells |
| Q28378687 | Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance |
| Q79188829 | Establishment of a rodent model of HIV-associated sensory neuropathy |
| Q40265937 | Evaluation of Bacillus anthracis thymidine kinase as a potential target for the development of antibacterial nucleoside analogs |
| Q28554599 | Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus |
| Q39867324 | Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay |
| Q35127088 | Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy |
| Q74223337 | Evidences that zidovudine (AZT) could not be directly responsible for iron overload in AZT-treated patients: an in vitro study |
| Q44916797 | Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production |
| Q41141176 | Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo |
| Q33554232 | Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants |
| Q36691909 | Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo |
| Q73585655 | Failure of AZT: a molecular perspective |
| Q36353945 | Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages |
| Q33393724 | Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection |
| Q33742501 | Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome |
| Q41843453 | Fermentative production of thymidine by a metabolically engineered Escherichia coli strain. |
| Q46516327 | First synthesis and antimicrobial activity Of N- and S-alpha-L-arabinopyranosyl-1,2,4-triazoles |
| Q37202263 | Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection |
| Q53566237 | Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC. |
| Q57810324 | Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors-In Silico Activity Prediction |
| Q73423116 | Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine |
| Q40159491 | Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. |
| Q41524971 | Glycosyl-oxycarbonylaminosulfonyl-2',3'-dideoxynucleoside derivatives as lipophilic nucleotide mimics. Synthesis and anti-HIV activity. |
| Q28316971 | Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine |
| Q56786269 | HIV Reverse Transcriptase Inhibitors |
| Q57064777 | HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy |
| Q27670634 | HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors |
| Q35853012 | HIV-1 antiretroviral drug therapy |
| Q36674581 | HIV-Specific Treatment |
| Q37043025 | Harnessing autophagy for cell fate control gene therapy |
| Q36646145 | Hematologic Effects of AIDS Therapies |
| Q45229763 | Hematological effects of 2',3'-dideoxycytidine in rabbits |
| Q28334930 | Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine |
| Q54246489 | How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy. |
| Q28249872 | Human foamy virus reverse transcription that occurs late in the viral replication cycle |
| Q34718174 | Human immunodeficiency virus reverse transcriptase substitutes for DNA polymerase I in Escherichia coli |
| Q28323550 | Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate |
| Q45710539 | Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children |
| Q23918962 | Human inter-individual variability in metabolism and genotoxic response to zidovudine |
| Q28367543 | Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine |
| Q34113323 | Immunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDV |
| Q33751841 | Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy |
| Q42801263 | Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. |
| Q33839401 | In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue |
| Q45844626 | In vitro activity of mannan sulfate, a novel sulfated polysaccharide, against human immunodeficiency virus type 1 and other enveloped viruses |
| Q42041046 | In vitro interactions between apricitabine and other deoxycytidine analogues |
| Q67488209 | In vitro toxicity of 3′‐azido‐3′‐deoxythymidine, carbovir and 2′, 3′‐didehydro‐2′, 3′‐dideoxythymidine to human and murine haematopoietic progenitor cells |
| Q28379471 | Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea |
| Q35185934 | Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action |
| Q35030873 | Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies |
| Q35263031 | Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides |
| Q34284455 | Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity |
| Q28293875 | Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients |
| Q33981459 | Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo |
| Q44575608 | Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphono methoxypropyl)adenine |
| Q28369350 | Inhibition of beta-globin gene expression by 3'-azido-3'-deoxythymidine in human erythroid progenitor cells |
| Q28359853 | Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides |
| Q28323481 | Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate |
| Q28341972 | Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet |
| Q28376476 | Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative |
| Q43915080 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate |
| Q28369221 | Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate |
| Q34264407 | Inhibition of immune functions by antiviral drugs |
| Q39782925 | Inhibition of murine leukemia virus with poly-2'-O-(2,4-dinitrophenyl)poly[A] |
| Q69060981 | Inhibition of reverse transcription in rat liver intracisternal A-particles by thymidine derivatives |
| Q80215893 | Inhibitors of HIV-1 reverse transcriptase |
| Q37783043 | Initial clinical experience with dideoxynucleosides as single agents and in combination therapy |
| Q54277165 | Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase |
| Q37288800 | Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells |
| Q34143531 | Intracellular accumulation of human immunodeficiency virus protease inhibitors |
| Q39869413 | Intracellular activity of zidovudine (3'-azido-3'-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2 |
| Q35125760 | Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients |
| Q36295462 | Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog |
| Q41915160 | Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent |
| Q36678586 | Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites |
| Q44657491 | Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection |
| Q78147943 | Intracellular phosphorylation of zidovudine in an in vitro hollow fiber model |
| Q33770095 | Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations |
| Q33745545 | Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure |
| Q73850566 | Involvement of multiple transporters in the oral absorption of nucleoside analogues |
| Q34442824 | Kinetic approaches to understanding the mechanisms of fidelity of the herpes simplex virus type 1 DNA polymerase |
| Q45859635 | Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150 |
| Q45786646 | Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase |
| Q42588415 | Lack of effect of lamivudine on Ebola virus replication |
| Q40312836 | Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients |
| Q33676340 | Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals |
| Q35867338 | Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats |
| Q51563075 | Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. |
| Q89108047 | Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator |
| Q35132164 | Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene |
| Q40936332 | Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals |
| Q28394866 | Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells |
| Q37270571 | Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction |
| Q37324745 | Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes |
| Q40931531 | MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs |
| Q33745955 | Management of HIV-infected pregnant patients in malaria-endemic areas: therapeutic and safety considerations in concomitant use of antiretroviral and antimalarial agents |
| Q40626125 | Management of antiretroviral drug therapy in human immunodeficiency virus infection |
| Q45753600 | Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection |
| Q73597514 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand |
| Q28343606 | Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants |
| Q24650946 | Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro |
| Q28368041 | Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine |
| Q54021581 | Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step. |
| Q36361723 | Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors |
| Q35122784 | Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription |
| Q37083800 | Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. |
| Q42277625 | Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase |
| Q41572972 | Mechanistic effects of kijimicin on inhibition of human immunodeficiency virus replication |
| Q38783855 | Membrane-permeable Triphosphate Prodrugs of Nucleoside Analogues |
| Q34200051 | Metabolic transformation of AZTp4A by Ap4A hydrolase regenerates AZT triphosphate |
| Q41095941 | Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes |
| Q40672674 | Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives |
| Q41578932 | Metabolism and mode of selective inhibition of human immunodeficiency virus replication by 3'-azido-2',3'-dideoxy-5-iodouridine and 3'-azido-2',3'-dideoxy-5-bromouridine |
| Q41644125 | Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus |
| Q44297954 | Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease |
| Q42201908 | Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus |
| Q62474411 | Mitochondria as Cell Targets of AZT (Zidovudine) |
| Q35550221 | Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective |
| Q34973688 | Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents |
| Q35124243 | Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation |
| Q59662994 | Modifying Human Thymidylate Kinase to Potentiate Azidothymidine Activation |
| Q45211779 | Modulated nucleoside kinases as tools to improve the activation of therapeutic nucleoside analogues |
| Q40719018 | Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger |
| Q44142327 | Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach |
| Q77569268 | Monitoring of intracellular levels of 5'-monophosphate-AZT using an enzyme immunoassay |
| Q40573911 | Monitoring the intracellular metabolism of nucleoside phosphoramidate pronucleotides by 31P NMR. |
| Q44180443 | Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. |
| Q40159476 | Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations |
| Q42009655 | Mutational analysis of Lys65 of HIV-1 reverse transcriptase |
| Q28471689 | N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance |
| Q35839880 | Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle |
| Q30414740 | Neurotoxic effects of AZT on developing and adult neurogenesis |
| Q41923505 | Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model |
| Q28342653 | Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine |
| Q44610767 | Novel synthesis of 4'C-aryl-branched acyclic nucleoside using [3,3]-sigmatropic rearrangement |
| Q28342789 | Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine |
| Q64902008 | Nucleoside Analogues as Antibacterial Agents. |
| Q41079192 | Nucleoside analogues previously found to be inactive against HIV may be activated by simple chemical phosphorylation |
| Q47592519 | Nucleoside diphosphate and triphosphate prodrugs - An unsolvable task? |
| Q38957596 | Nucleoside mono- and diphosphate prodrugs of 2',3'-dideoxyuridine and 2',3'-dideoxy-2',3'-didehydrouridine |
| Q63976995 | Organometallic Nucleoside Analogues: Effect of Hydroxyalkyl Linker Length on Cancer Cell Line Toxicity |
| Q39692591 | Pathogenesis of human immunodeficiency virus infection and prospects for control |
| Q37816389 | Pediatric antiretroviral therapy |
| Q41474530 | PharmGKB summary: zidovudine pathway |
| Q37251569 | Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy |
| Q40430974 | Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection |
| Q38624965 | Pharmacokinetic considerations in the use of antivirals in neonates. |
| Q43038391 | Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team |
| Q41293013 | Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships |
| Q35262604 | Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys |
| Q58292513 | Pharmacokinetics of Zidovudine in HIV-Positive Patients with Liver Disease |
| Q35965780 | Pharmacokinetics of antiretrovirals in pregnant women |
| Q33980114 | Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers |
| Q33754634 | Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus |
| Q37783044 | Pharmacologic studies of nucleosides active against the human immunodeficiency virus |
| Q34481359 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection |
| Q35576980 | Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I |
| Q37783039 | Pharmacology of antiretroviral drugs. Lessons learned to date |
| Q39652022 | Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus |
| Q36485086 | Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses |
| Q45763995 | Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus |
| Q28323864 | Phosphatidylazidothymidine. Mechanism of antiretroviral action in CEM cells |
| Q28340356 | Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate |
| Q22010485 | Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme |
| Q31975873 | Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians |
| Q28139775 | Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases |
| Q34132910 | Plant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapy |
| Q79938831 | Plasma and cellular markers of 3'-azido-3'-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs |
| Q44043123 | Polymer-supported reagents for methylphosphorylation and phosphorylation of carbohydrates |
| Q28323740 | Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase |
| Q35807808 | Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease |
| Q45177265 | Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis |
| Q40043127 | Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine |
| Q59417289 | Prodrugs of Nucleoside Triphosphates as a Sound and Challenging Approach: A Pioneering Work That Opens a New Era in the Direct Intracellular Delivery of Nucleoside Triphosphates |
| Q40732367 | Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA. |
| Q33938281 | Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. |
| Q35129433 | Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. |
| Q35855478 | Reactivation of thymidine kinase-defective herpes simplex virus is enhanced by nucleoside |
| Q34690268 | Recent progress in artificial receptors for phosphate anions in aqueous solution |
| Q45840449 | Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome |
| Q36748898 | Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy |
| Q40621685 | Replication Kinetics for Divergent Type 1 Human Immunodeficiency Viruses Using Quantitative SYBR Green I Real-Time Polymerase Chain Reaction |
| Q41919457 | Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections |
| Q39868483 | Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase |
| Q37085569 | Restoration of the antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells |
| Q28338459 | Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine |
| Q54599332 | Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. |
| Q22242815 | Reverse transcription of the HIV-1 pandemic |
| Q28361577 | Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro |
| Q28337829 | Ribavirin antagonizes the effect of azidothymidine on HIV replication |
| Q74546234 | Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine |
| Q34478584 | Role of nucleoside diphosphate kinase in the activation of anti-HIV nucleoside analogs |
| Q40762082 | S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs |
| Q34058234 | SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. |
| Q40668077 | SYBR Green II Dye-Based Real-Time Assay for Measuring Inhibitor Activity Against HIV-1 Reverse Transcriptase. |
| Q34347099 | Science, medicine and clinical pharmacology. The Lilly Lecture 1994. |
| Q57637247 | Separation of individual antiviral nucleotide prodrugs from synthetic mixtures using cross-reactivity of a molecularly imprinted stationary phase |
| Q36331864 | Sex differences in antiretroviral therapy-associated intolerance and adverse events |
| Q41643977 | Significant Anti-HIV Activity of New Modified Poly Anionic Polymersin vitro |
| Q33744806 | Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection |
| Q43797460 | Simple synthesis and anti-HIV activity of novel 3'-vinyl branched apiosyl pyrimidine nucleosides |
| Q73814738 | Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography |
| Q38583674 | Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry |
| Q68048909 | Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography |
| Q39537216 | Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals |
| Q33977187 | Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection |
| Q46542036 | Solid-supported diphosphitylating and triphosphitylating reagents for nucleoside modification |
| Q89738253 | Stabilization of Active Site Dynamics Leads to Increased Activity with 3'-Azido-3'-deoxythymidine Monophosphate for F105Y Mutant Human Thymidylate Kinase |
| Q41155364 | Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection |
| Q33285486 | Stereochemistry of rHint1 hydrolase assisted cleavage of P-N bond in nucleoside 5'-O-phosphoramidothioates |
| Q44867894 | Stereoselective synthesis of novel 4'-branched and bicyclo[3.1.0]hexane-templated nucleoside |
| Q38172146 | Strategies for antiviral therapy in AIDS. |
| Q35930774 | Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy |
| Q46963527 | Structural investigation of protonated azidothymidine and protonated dimer |
| Q33896402 | Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition |
| Q27741328 | Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation |
| Q28342189 | Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1 |
| Q24558609 | Structures of thymidine kinase 1 of human and mycoplasmic origin |
| Q35859433 | Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively |
| Q28620349 | Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases |
| Q28623694 | Substrate specificity of human nucleoside-diphosphate kinase revealed by transient kinetic analysis |
| Q64052506 | Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine |
| Q72611356 | Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity |
| Q28323570 | Synergistic Inhibition of Human Immunodeficiency Virus Replication In Vitro by Combinations of 3′-Azido-3′-Deoxythymidine and 3′-Fluoro-3′-Deoxythymidine |
| Q28338307 | Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro |
| Q34597465 | Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors |
| Q34041566 | Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs |
| Q44358150 | Synthesis and anti-HIV activity of carbamates of antiviral agent stavudine |
| Q44998474 | Synthesis and antiviral activity of novel 2',4'-doubly branched carbocyclic nucleosides |
| Q44618706 | Synthesis and antiviral activity of novelc-methyl branched cyclopropyl nucleosides |
| Q40983982 | Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates |
| Q44836943 | Synthesis and antiviral evaluation of novel 4'-hydroxymethyl branched apiosyl nucleosides |
| Q28377690 | Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues |
| Q43506637 | Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir. |
| Q40537429 | Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug araC. |
| Q40452331 | Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA. |
| Q40540059 | Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triesters |
| Q43980402 | Synthesis and in vitro antibacterial activity of novel 5'-O-analog derivatives of zidovudine as potential prodrugs |
| Q43828119 | Synthesis and photophysical study of highly luminescent coordination compounds of rare earth ions with thenoyltrifluoroacetonate and AZT. |
| Q54170339 | Synthesis of a photoaffinity analog of 3'-azidothymidine, 5-azido-3'-azido-2',3'-dideoxyuridine. Interactions with herpesvirus thymidine kinase and cellular enzymes. |
| Q38473352 | Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation |
| Q40659884 | Synthesis of novel apionucleosides: a short and concise synthesis of 2-deoxyapio-L-furanosyl acetate from D-lactose |
| Q36403831 | Synthesis, Binding and Antiviral Properties of Potent Core-Extended Naphthalene Diimides Targeting the HIV-1 Long Terminal Repeat Promoter G-Quadruplexes |
| Q40023090 | Synthesis, characterization, and in vitro assay of folic acid conjugates of 3'-azido-3'-deoxythymidine (AZT): toward targeted AZT based anticancer therapeutics. |
| Q36624697 | Teratogenic and embryocidal effects of Zidovudine (AZT) in sprague-dawley rats |
| Q43744211 | Testing the reverse transcriptase model of somatic mutation |
| Q34313605 | The "Connection" Between HIV Drug Resistance and RNase H |
| Q61928289 | The Role of Mitochondria in HIV Infection and Its Treatment |
| Q28378929 | The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate |
| Q44590334 | The binding of HIV-1 protease inhibitors to human serum proteins |
| Q42278288 | The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine |
| Q59663013 | The bottleneck in AZT activation |
| Q24655011 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic |
| Q50174914 | The effect of thymidine on the antibacterial and antiviral activity of zidovudine |
| Q33972465 | The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy? |
| Q41612943 | The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells |
| Q37651211 | The mitochondrial DNA polymerase in health and disease. |
| Q40662335 | The molecular biology of HIV. Insights into pathogenesis and targets for therapy. |
| Q28279752 | The renaissance of fixed dose combinations: Combivir |
| Q94502289 | The road to new antiviral therapies |
| Q38088840 | The role of thymidine kinase in cancer diseases |
| Q41730377 | The stability of intracellular zidovudine and its anabolites in extracts of peripheral blood mononuclear cells (PBMCs). |
| Q35948245 | The synthesis of branched-chain 3'-C-cyanomethyl-2',3'-dideoxy sugar nucleosides of adenine as potential inhibitors of the human immunodeficiency virus |
| Q41703445 | The thymidylate kinase genes from Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus confer 3'-azido-3'-deoxythymidine resistance to Escherichia coli. |
| Q39866548 | The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy |
| Q41394569 | The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy |
| Q31779475 | The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance. |
| Q28909271 | The yeast Cdc8 exhibits both deoxythymidine monophosphate and diphosphate kinase activities |
| Q42123919 | Theoretical and Experimental: The Synthetic and Anion-Binding Properties of Tripodal Salicylaldehyde Derivatives |
| Q40431573 | Therapeutic Approaches to HIV Infection Based on Virus Structure and the Host Pathogen Interaction |
| Q45753597 | Timing and mechanism of perinatal human immunodeficiency virus-1 infection |
| Q48520747 | Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice |
| Q42077880 | Toward hyperpolarized molecular imaging of HIV: synthesis and longitudinal relaxation properties of (15) N-Azidothymidine |
| Q30649947 | Towards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles |
| Q35537911 | Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro |
| Q51795099 | Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. |
| Q33933489 | Transport, metabolism and elimination mechanisms of anti-HIV agents |
| Q37032793 | Treatment of adult T-cell leukemia/lymphoma: past, present, and future |
| Q33740357 | Treatment of human immunodeficiency virus infections |
| Q45385690 | Trimethoprim-sulfamethoxazole exposure alters ex vivo function of B lymphocytes isolated from human immunodeficiency virus-infected patients receiving Zidovudine |
| Q35788052 | Triple nucleoside reverse transcriptase inhibitor therapy in children |
| Q37770831 | Twenty-five years of translational medicine in antiretroviral therapy: promises to keep |
| Q35900776 | Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine |
| Q28369244 | Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism |
| Q28378905 | Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 |
| Q28361147 | Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity |
| Q36822667 | Use of recombinant retroviruses to characterize the activity of antiretroviral compounds |
| Q34101462 | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. |
| Q35979700 | Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae |
| Q28330687 | Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment |
| Q37034618 | Viral drug resistance and fitness. |
| Q40762611 | Viral gene products and replication of the human immunodeficiency type 1 virus |
| Q35172760 | Viruses, chemotherapy and immunity |
| Q24676814 | Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides |
| Q53565339 | Vitamins C and E prevent AZT-induced leukopenia and loss of cellularity in bone marrow. Studies in mice. |
| Q39098252 | Xenobiotic transporters and kidney injury |
| Q74530061 | Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver |
| Q44041583 | Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells |
| Q34194561 | Zidovudine and Lamivudine for HIV Infection. |
| Q40220433 | Zidovudine inhibits protein kinase C activity in human chronic myeloid (K562) cells. |
| Q42264778 | Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. |
| Q45767976 | Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus |
| Q40901291 | Zidovudine toxicity. Clinical features and management |
| Q37943002 | Zidovudine update: 1990. |
| Q35821683 | Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells |
| Q38649719 | Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy |
| Q53854055 | [Options in HIV therapy: present and future]. |
| Q28370101 | ddC- and 3TC-bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency |
Search more.